Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: Results from the Eastern Cooperative Oncology Group E2197 study

Lawrence J. Solin, Robert Gray, Lori J. Goldstein, Abram Recht, Frederick L. Baehner, Steven Shak, Sunil Badve, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Joseph A. Sparano

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The present study was performed to evaluate the significance of biologic subtype and 21-gene recurrence score relative to local recurrence and local-regional recurrence after breast conservation treatment with radiation. Eastern Cooperative Oncology Group E2197 was a prospective randomized clinical trial that compared two adjuvant systemic chemotherapy regimens for patients with operable breast carcinoma with 1-3 positive lymph nodes or negative lymph nodes with tumor size [1.0 cm. The study population was a subset of 388 patients with known 21-gene recurrence score and treated with breast conservation surgery, systemic chemotherapy, and definitive radiation treatment. Median follow-up was 9.7 years (range = 3.7-11.6 years). The 10-year rates of local recurrence and local-regional recurrence were 5.4 % and 6.6 %, respectively. Neither biologic subtype nor 21-gene Recurrence Score was associated with local recurrence or local-regional recurrence on univariate or multivariate analyses (all P C 0.12). The 10-year rates of local recurrence were 4.9 % for hormone receptor positive, HER2-negative tumors, 6.0 % for triple negative tumors, and 6.4 % for HER2-positive tumors (P = 0.76), and the 10-year rates of local-regional recurrence were 6.3, 6.9, and 7.2 %, respectively (P = 0.79). For hormone receptorpositive tumors, the 10-year rates of local recurrence were 3.2, 2.9, and 10.1 % for low, intermediate, and high 21-gene recurrence score, respectively (P = 0.17), and the 10-year rates of local-regional recurrence were 3.8, 5.1, and 12.0 %, respectively (P = 0.12). For hormone receptor-positive tumors, the 21-gene recurrence score evaluated as a continuous variable was significant for local-regional recurrence (hazard ratio 2.66; P - 0.03). The 10-year rates of local recurrence and local-regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation.

Original languageEnglish (US)
Pages (from-to)683-692
Number of pages10
JournalBreast Cancer Research and Treatment
Volume134
Issue number2
DOIs
StatePublished - Jul 2012

Fingerprint

Breast
Radiation
Breast Neoplasms
Recurrence
Genes
Therapeutics
Neoplasms
Hormones
Lymph Nodes
Adjuvant Chemotherapy
Multivariate Analysis
Randomized Controlled Trials

Keywords

  • 21-gene recurrence score
  • Breast conservation treatment
  • Early stage breast carcinoma
  • Local recurrence
  • Local-regional recurrence
  • Radiation treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma : Results from the Eastern Cooperative Oncology Group E2197 study. / Solin, Lawrence J.; Gray, Robert; Goldstein, Lori J.; Recht, Abram; Baehner, Frederick L.; Shak, Steven; Badve, Sunil; Perez, Edith A.; Shulman, Lawrence N.; Martino, Silvana; Davidson, Nancy E.; Sledge, George W.; Sparano, Joseph A.

In: Breast Cancer Research and Treatment, Vol. 134, No. 2, 07.2012, p. 683-692.

Research output: Contribution to journalArticle

Solin, Lawrence J. ; Gray, Robert ; Goldstein, Lori J. ; Recht, Abram ; Baehner, Frederick L. ; Shak, Steven ; Badve, Sunil ; Perez, Edith A. ; Shulman, Lawrence N. ; Martino, Silvana ; Davidson, Nancy E. ; Sledge, George W. ; Sparano, Joseph A. / Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma : Results from the Eastern Cooperative Oncology Group E2197 study. In: Breast Cancer Research and Treatment. 2012 ; Vol. 134, No. 2. pp. 683-692.
@article{5240cc297193418aa404e675df525596,
title = "Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: Results from the Eastern Cooperative Oncology Group E2197 study",
abstract = "The present study was performed to evaluate the significance of biologic subtype and 21-gene recurrence score relative to local recurrence and local-regional recurrence after breast conservation treatment with radiation. Eastern Cooperative Oncology Group E2197 was a prospective randomized clinical trial that compared two adjuvant systemic chemotherapy regimens for patients with operable breast carcinoma with 1-3 positive lymph nodes or negative lymph nodes with tumor size [1.0 cm. The study population was a subset of 388 patients with known 21-gene recurrence score and treated with breast conservation surgery, systemic chemotherapy, and definitive radiation treatment. Median follow-up was 9.7 years (range = 3.7-11.6 years). The 10-year rates of local recurrence and local-regional recurrence were 5.4 {\%} and 6.6 {\%}, respectively. Neither biologic subtype nor 21-gene Recurrence Score was associated with local recurrence or local-regional recurrence on univariate or multivariate analyses (all P C 0.12). The 10-year rates of local recurrence were 4.9 {\%} for hormone receptor positive, HER2-negative tumors, 6.0 {\%} for triple negative tumors, and 6.4 {\%} for HER2-positive tumors (P = 0.76), and the 10-year rates of local-regional recurrence were 6.3, 6.9, and 7.2 {\%}, respectively (P = 0.79). For hormone receptorpositive tumors, the 10-year rates of local recurrence were 3.2, 2.9, and 10.1 {\%} for low, intermediate, and high 21-gene recurrence score, respectively (P = 0.17), and the 10-year rates of local-regional recurrence were 3.8, 5.1, and 12.0 {\%}, respectively (P = 0.12). For hormone receptor-positive tumors, the 21-gene recurrence score evaluated as a continuous variable was significant for local-regional recurrence (hazard ratio 2.66; P - 0.03). The 10-year rates of local recurrence and local-regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation.",
keywords = "21-gene recurrence score, Breast conservation treatment, Early stage breast carcinoma, Local recurrence, Local-regional recurrence, Radiation treatment",
author = "Solin, {Lawrence J.} and Robert Gray and Goldstein, {Lori J.} and Abram Recht and Baehner, {Frederick L.} and Steven Shak and Sunil Badve and Perez, {Edith A.} and Shulman, {Lawrence N.} and Silvana Martino and Davidson, {Nancy E.} and Sledge, {George W.} and Sparano, {Joseph A.}",
year = "2012",
month = "7",
doi = "10.1007/s10549-012-2072-y",
language = "English (US)",
volume = "134",
pages = "683--692",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma

T2 - Results from the Eastern Cooperative Oncology Group E2197 study

AU - Solin, Lawrence J.

AU - Gray, Robert

AU - Goldstein, Lori J.

AU - Recht, Abram

AU - Baehner, Frederick L.

AU - Shak, Steven

AU - Badve, Sunil

AU - Perez, Edith A.

AU - Shulman, Lawrence N.

AU - Martino, Silvana

AU - Davidson, Nancy E.

AU - Sledge, George W.

AU - Sparano, Joseph A.

PY - 2012/7

Y1 - 2012/7

N2 - The present study was performed to evaluate the significance of biologic subtype and 21-gene recurrence score relative to local recurrence and local-regional recurrence after breast conservation treatment with radiation. Eastern Cooperative Oncology Group E2197 was a prospective randomized clinical trial that compared two adjuvant systemic chemotherapy regimens for patients with operable breast carcinoma with 1-3 positive lymph nodes or negative lymph nodes with tumor size [1.0 cm. The study population was a subset of 388 patients with known 21-gene recurrence score and treated with breast conservation surgery, systemic chemotherapy, and definitive radiation treatment. Median follow-up was 9.7 years (range = 3.7-11.6 years). The 10-year rates of local recurrence and local-regional recurrence were 5.4 % and 6.6 %, respectively. Neither biologic subtype nor 21-gene Recurrence Score was associated with local recurrence or local-regional recurrence on univariate or multivariate analyses (all P C 0.12). The 10-year rates of local recurrence were 4.9 % for hormone receptor positive, HER2-negative tumors, 6.0 % for triple negative tumors, and 6.4 % for HER2-positive tumors (P = 0.76), and the 10-year rates of local-regional recurrence were 6.3, 6.9, and 7.2 %, respectively (P = 0.79). For hormone receptorpositive tumors, the 10-year rates of local recurrence were 3.2, 2.9, and 10.1 % for low, intermediate, and high 21-gene recurrence score, respectively (P = 0.17), and the 10-year rates of local-regional recurrence were 3.8, 5.1, and 12.0 %, respectively (P = 0.12). For hormone receptor-positive tumors, the 21-gene recurrence score evaluated as a continuous variable was significant for local-regional recurrence (hazard ratio 2.66; P - 0.03). The 10-year rates of local recurrence and local-regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation.

AB - The present study was performed to evaluate the significance of biologic subtype and 21-gene recurrence score relative to local recurrence and local-regional recurrence after breast conservation treatment with radiation. Eastern Cooperative Oncology Group E2197 was a prospective randomized clinical trial that compared two adjuvant systemic chemotherapy regimens for patients with operable breast carcinoma with 1-3 positive lymph nodes or negative lymph nodes with tumor size [1.0 cm. The study population was a subset of 388 patients with known 21-gene recurrence score and treated with breast conservation surgery, systemic chemotherapy, and definitive radiation treatment. Median follow-up was 9.7 years (range = 3.7-11.6 years). The 10-year rates of local recurrence and local-regional recurrence were 5.4 % and 6.6 %, respectively. Neither biologic subtype nor 21-gene Recurrence Score was associated with local recurrence or local-regional recurrence on univariate or multivariate analyses (all P C 0.12). The 10-year rates of local recurrence were 4.9 % for hormone receptor positive, HER2-negative tumors, 6.0 % for triple negative tumors, and 6.4 % for HER2-positive tumors (P = 0.76), and the 10-year rates of local-regional recurrence were 6.3, 6.9, and 7.2 %, respectively (P = 0.79). For hormone receptorpositive tumors, the 10-year rates of local recurrence were 3.2, 2.9, and 10.1 % for low, intermediate, and high 21-gene recurrence score, respectively (P = 0.17), and the 10-year rates of local-regional recurrence were 3.8, 5.1, and 12.0 %, respectively (P = 0.12). For hormone receptor-positive tumors, the 21-gene recurrence score evaluated as a continuous variable was significant for local-regional recurrence (hazard ratio 2.66; P - 0.03). The 10-year rates of local recurrence and local-regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation.

KW - 21-gene recurrence score

KW - Breast conservation treatment

KW - Early stage breast carcinoma

KW - Local recurrence

KW - Local-regional recurrence

KW - Radiation treatment

UR - http://www.scopus.com/inward/record.url?scp=84868194039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868194039&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2072-y

DO - 10.1007/s10549-012-2072-y

M3 - Article

C2 - 22547108

AN - SCOPUS:84868194039

VL - 134

SP - 683

EP - 692

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -